Emagix is focused on improving diagnosis and assessment measures by analysing blood flow dynamics. Our proprietary software algorithm provides an objective assessment of which blood vessels are compromised, and to what extent. This vital tool gives clinicians the information they need to diagnose disease earlier, and to provide treatment that is better focused, in order to stop disease progression in its tracks.
FOUNDER & CEO - ALON FRIEDMAN, MD PHD
As a Professor of Neuroscience, Dr. Friedman has held the Dennis Chair in Epilepsy Research in the Medical Faculty at Dalhousie University since 2014. Previously, he has also served as a Professor in the Department of Physiology and Cell Biology at the Ben-Gurion University of the Negev, Faculty of Health Sciences.
Between 2011 and 2014, Dr. Friedman acted as the director of the Zlotowski Center for Neuroscience and led the establishment of the new Interfaculty School for Brain Sciences, at Ben-Gurion University. In 2007 Dr. Friedman won the prestigious Michael Prize for Epilepsy research on his discoveries on the role of vascular pathology in epilepsy. Dr. Friedman's research focuses on how nerve cells, glia, and vasculature, interact to underlie abnormal brain functions following traumatic and ischemic brain injuries.
Dr. Friedman has published over 110 papers and chapters in books and submitted 5 patents on diagnosis and treatment of brain disorders. He has extensive experience in basic, translational, and clinical research on pathologies arising from vascular integrity in the central nervous system (CNS), development, and implementation of novel imaging methods for the diagnosis of vascular pathology using analysis algorithms for evaluation of blood-neural barrier integrity.
VP, BD&L - Christopher J. Barden, PhD
A management/IP consultant, serial entrepreneur, and co-founder of several companies in the life sciences and medical technology spaces, Chris is a seasoned dealmaker. He has 20 years of experience on the operational side of such businesses, 10 of which he has spent negotiating preclinical/clinical collaboration, service, and license agreements with pharmaceutical and medical device companies. Chris has a scientific background in computational science and is a US registered patent agent, which gives him a unique skill set for understanding medical technologies and the drivers to achieving “win-win” partnerships.
cto - jim kukurin, bsc, bsc, basc
Jim has a broad background in the sciences, with degrees in Biology, Computer Science, and Biomedical Engineering. He has entrepreneurial experience as the co-founder of an I.T. support company, and a decade of working with clients in diverse fields, including telecommunications, healthcare, education, and advertising.
LYNA KAMINTSKY, MSC, PHD
Lyna is applying her background in biomedical engineering to develop imaging algorithms for the analysis of retinal and brain disorders. She completed her Ph.D. in Medical Neuroscience at Dalhousie University and her collaboration with Emagix has been recognized with the 2018 MITACS award for Outstanding Innovation.
COLYN MUNN, BSC
Colyn received his BSc. in Engineering from the University of New Brunswick in 2018 and is currently registered as an EIT with Engineers Nova Scotia. Colyn has worked as a Programmer and Data Analyst for the Institute of Biomedical Engineering where he assisted Lower-Limb Dermoskeleton and gait research. He also collaborated with the Atlantic Clinic for Upper Limb Prosthetics to design the Single Site Myoelectric Controller which received the Irving Oil Plant Design Competition award in 2018.
SHAI LIPKOVICH B.COMM
DANIELA KAUFER, PHD
Professor of Neuroscience, UC Berkeley, CA
Daniela Kaufer received her PhD in Molecular Neuroscience from the Hebrew University in Jerusalem, and was a Human Frontiers Science Foundation and Life Science Research Foundation Postdoctoral Fellow at the departments of Biological Sciences and Neurosurgery at Stanford University. She is currently an Associate Professor in the Integrative Biology Department and the Helen Wills Neuroscience Institute at UC Berkeley. Research in the Kaufer lab focuses on the events that follow microvascular and blood-brain barrier pathology as well as plasticity of the brain in the face of stress and neurological insults throughout life.
Dr. Kaufer has published in numerous journals including Nature Neuroscience, Nature, The Proceedings of the National Academy of Sciences, Journal of Neuroscience, Molecular Psychiatry, Nature Medicine, eLIFE, and Science. Professor Kaufer is the recipient of the 2010 National Institute of Mental Health Director's New Innovator Award (BRAINS), NARSAD Young and Independent Investigator Awards, and the 2013 BAKAR Fellows Award.
OREN TOMKINS - NETZER, MD, PHD
Research & Clinical Consultant
Director of Ophthalmology, Ophthalmic Department
Carmel Medical Center
Dr. Tomkins-Netzer is an opthalmologist and retina specialist. His clinical practice includes widespread retinal diseases as well as uveitis. He is director of ophthalmology at Carmel Medical Center in Haifa, Israel. The main research focus of his research group is on treatment and outcome of uveitis, as well as novel diagnostic approaches to retinal diseases using angiography and optical coherence tomography imaging methods.
YONATAN SERLIN, MD
Research & Clinical Consultant
Neurology Training Program, McGill University, Montreal, QC
Dr. Serlin earned his B. Med Sc., and MD Degrees from the Joyce and Irving Goldman Medical School, Ben-Gurion University, Beer-Sheva, Israel. He completed his post-doctoral research fellowship at the Department of Medical Neuroscience, Faculty of Medicine, Dalhousie University.
Emagix is working with multiple organizations to further develop and improve its ability to deliver analysis that provides effective diagnostic assistance to clinicians:
Innovacorp invests in early stage Nova Scotia entrepreneurs, combining venture capital with business mentoring and incubation facilities.
Bionova leads, accelerates, and advocates for Nova Scotia’s growing health and life sciences sector. Since 1993, BioNova has been accelerating the growth of its member companies. By hosting networking and educational events, and providing connections to potential funders and business resources, BioNova helps companies succeed.
Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company that is developing clinical programs focused on the central nervous system. Current areas of investigation include pain management, infectious diseases, and cognitive impairment due to traumatic brain injury.